

## Supplementary

**Table S1** Prognosis of patients with LC and CTD in previously published studies

Study	Year	Study design	No. of patients with CA&CTD	CTD type	Cancer type	Median survival (months)	Median follow-up (months)
Adzic (25)	2007	RC	24	Multiple	LC	5.0	NA
Enomoto (27)	2016	RC	7	CTD-ILD	LC	7.0	67.4
Saigo (28)	2017	RC	27	Multiple	LC	39.3	14.9
Nayak (8)	2017	RC	3820	RA	BC	85.2	NA
					PC	87.6	
					CRC	33.6	
					LC	10.8	
Andras (26)	2019	RC	43	IIM	Multiple	16.0	NA
Zhang (29)	2020	RC	54	RA	LC	16.0	NA
This study	2020	RC	84	Multiple	LC	21.0	65.0

CA&CTD, cancer with connective tissue disease; CTD, connective tissue disease; RC, retrospective cohort; LC, lung cancer; CRC, colorectal cancer; BC, breast cancer; PC, prostate cancer; RA, rheumatoid arthritis; CTD-ILD, connective tissue disease-related interstitial lung disease; IIM, idiopathic inflammatory myopathy; NA, not available.